94例肺癌患者血清CEA、CA125、CA19—9检测结果分析

目的：探讨血清癌胚抗原（CEA）、CA125、CAl9—9测定在肺癌的诊断和预后判断中的应用价值。方法：回顾性分析2010年05月-2011年05月我院收活的94例肺癌患者化疗前后血清CEA、CAl25、CAl9—9水平检测结果，并与良性肺病组和健康对照组作对比分析。结果：肺癌患者血清CEA、CAl25、CAl9—9水平明显高于良性肺病组和健康对照组，差异均有统计学意义（P〈0．05）；化疗有效组治疗后CEA和CAl25水平较治疗前明显下降，差异有统计学意义（P〈0．05）。结论：血清CEA、CAl25、CAl9—9水平检测对肺癌诊断和预后判断有较好应用价值；血清CEA和CAl25水平的变化对晚期肺癌患者化疗效果的判断有一定价值。

94 cases of lung cancer patients with CEA, CA125, CA19-9 Analysis of test results

Objective： to study the serum carcinoma embryo antigen （CEA）, CA125, CA19 - 9 determination in lung cancer diagnosis and prognosis application value judgment. Methods： A retrospective analysis of may 2010 - may 2011 were 94 cases of our patients with lung cancer chemotherapy serum C E before A and C A1 2 5, C A19 - 9 test results, and with benign pulmonary disease group compared with healthy controls. Results： lung cancer patients serum C E A, C A 1 2 5, C A1 9 - 9 level obviously higher than benign pulmonary disease group and healthy contxols, are highly statistically significant difference （P 〈 0.0 5）, chemotherapy effective treatment group C E after A and C A 12 5 more before treatment dropped significantly, difference was statistically significant （P 〈 0.0 5）. Conclusion： the serum CA 125, CEA, detecting cal9 - 9 leel of lung cancer diagnosis and prognostic has good application value. Serum C E A and C AI 2 5 levels of change on advanced cancer patients have cerlain curative effect judgment value.